Efficacy of Tocilizumab Therapy in Different Subtypes of COVID-19 Cytokine Storm Syndrome
Background: Cytokine storm in COVID-19 is heterogenous. There are at least three subtypes: cytokine release syndrome (CRS), macrophage activation syndrome (MAS), and sepsis. Methods: A retrospective study comprising 276 patients with SARS-CoV-2 pneumonia. All patients were tested for ferritin, inter...
Main Authors: | Oleksandr Oliynyk, Wojciech Barg, Anna Slifirczyk, Yanina Oliynyk, Vitaliy Gurianov, Marta Rorat |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-06-01
|
Series: | Viruses |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4915/13/6/1067 |
Similar Items
-
Treatment Options during Cytokine Storm
by: Abdullah Alkattan, et al.
Published: (2021-04-01) -
Recent updates in the clinical trials of therapeutic monoclonal antibodies targeting cytokine storm for the management of COVID-19
by: Shikha Patel, et al.
Published: (2021-02-01) -
The Imperfect Cytokine Storm
by: Vinh Q. Chau, MD, et al.
Published: (2020-07-01) -
Comparison of the Effect of Unfractionated Heparin and Enoxaparin Sodium at Different Doses on the Course of COVID-19-Associated Coagulopathy
by: Oleksandr Oliynyk, et al.
Published: (2021-09-01) -
The therapeutic potential of gelsolin in attenuating cytokine storm, ARDS, and ALI in severe COVID-19
by: Juan Zhi, et al.
Published: (2024-07-01)